The quarterly journal of experimental psychology

The year 2015 marks the 30th birthday of DC (Difference of Convex functions) programming and DCA (DC Algorithms) which constitute the backbone of nonconvex programming and global optimization. In this article we offer a short survey on thirty years of developments of these theoretical and algorithmic tools. The survey is comprised of three parts. In the first part we present a brief history of the field, while in the second we summarize the state-of-the-art results and recent advances. We focus on main theoretical results and DCA solvers for important classes of difficult nonconvex optimization problems, and then give an overview of real-world applications whose solution methods are based on DCA. The third part is devoted to new trends and important open issues, as well as suggestions for future developments.

DC programming and DCA: thirty years of developments

Since its introduction in the early nineties as a promising functional imaging technique in the management of neoplastic disorders, FDG-PET, and subsequently FDG-PET/CT, has become a cornerstone in several oncologic procedures such as tumor staging and restaging, treatment efficacy assessment during or after treatment end and radiotherapy planning. Moreover, the continuous technological progress of image generation and the introduction of sophisticated software to use PET scan as a biomarker paved the way to calculate new prognostic markers such as the metabolic tumor volume (MTV) and the total amount of tumor glycolysis (TLG). FDG-PET/CT proved more sensitive than contrast-enhanced CT scan in staging of several type of lymphoma or in detecting widespread tumor dissemination in several solid cancers, such as breast, lung, colon, ovary and head and neck carcinoma. As a consequence the stage of patients was upgraded, with a change of treatment in 10%–15% of them. One of the most evident advantages of FDG-PET was its ability to detect, very early during treatment, significant changes in glucose metabolism or even complete shutoff of the neoplastic cell metabolism as a surrogate of tumor chemosensitivity assessment. This could enable clinicians to detect much earlier the effectiveness of a given antineoplastic treatment, as compared to the traditional radiological detection of tumor shrinkage, which usually takes time and occurs much later.

https://www.mdpi.com/2072-6694/6/4/1821/pdf

Positron Emission Tomography (PET) in Oncology

This work surveys essential properties of the so-called copositive matrices, the study of which has been spread over more than fifty-five years. Special emphasis is given to variational aspects related to the concept of copositivity. In addition, some new results on the geometry of the cone of copositive matrices are presented here for the first time.

/pdf/a-variational-approach-to-copositive-matrices-5g9lwgtxmp.pdf

A Variational Approach to Copositive Matrices

(18)F-FDG PET/CT has become the reference standard in oncologic imaging against which the performance of other imaging modalities is measured. The promise of PET/MRI includes multiparametric imaging to further improve diagnosis and phenotyping of cancer. Rather than focusing on these capabilities, many investigators have examined whether (18)F-FDG PET combined with mostly anatomic MRI improves cancer staging and restaging. After a description of PET/MRI scanner designs and a discussion of technical and operational issues, we review the available literature to determine whether cancer assessments are improved with PET/MRI. The available data show that PET/MRI is feasible and performs as well as PET/CT in most types of cancer. Diagnostic advantages may be achievable in prostate cancer and in bone metastases, whereas disadvantages exist in lung nodule assessments. We conclude that (18)F-FDG PET/MRI and PET/CT provide comparable diagnostic information when MRI is used simply to provide the anatomic framework. Thus, PET/MRI could be used in lieu of PET/CT if this approach becomes economically viable and if reasonable workflows can be established. Future studies should explore the multiparametric potential of MRI.

https://jnm.snmjournals.org/content/jnumed/57/3/420.full.pdf

18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients

PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer (PCa), but its clinical use was promptly extended to detection, staging and therapy response assessment. The expanding use of PSMA PET worldwide has also revealed PSMA ligand uptake in diverse nonprostatic diseases, which raised questions about the specificity of this imaging modality. Although not very common initially, a growing number of pathologies presenting PSMA uptake on PET have been reported in the last few years, and a proper interpretation of PSMA PET imaging findings suddenly became challenging and, to some extent, confusing. Compared to cytoplasmic PSMA expression in nonprostatic cells, the molecular features of apical PSMA expression in PCa cells can help to distinguish these various conditions. Correlations of imaging findings to patient history, to the expected pattern of disease spread and mainly to computed tomography (CT) and/or magnetic resonance imaging (MRI) characteristics will reinforce the distinction of lesions that are more likely related to PCa from those that could lead to an incorrect diagnosis. The overall benefits of endothelial PSMA expression, which is associated with the neovasculature of malignant neoplasms, will be highlighted, stating the potential use of PSMA ligand uptake as a theranostic tool. This review aims to cover the collection of nonprostatic diseases, including benign and malignant tumors, in a didactic approach according to disease etiology, with discussion of bone-related conditions and inflammatory and infectious processes.

/pdf/nonprostatic-diseases-on-psma-pet-imaging-a-spectrum-of-4l2zgobuz8.pdf

Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings

To compare the diagnostic accuracy of PET/MRI and PET/CT for staging and re-staging advanced gynaecological cancer patients as well as identify the potential benefits of each method in such a population. Twenty-six patients with suspicious or proven advanced gynaecological cancer (12 ovarian, seven cervical, one vulvar and four endometrial tumours, one uterine metastasis, and one primary peritoneal cancer) underwent whole-body imaging with a sequential trimodality PET/CT/MR system. Images were analysed regarding primary tumour detection and delineation, loco-regional lymph node staging, and abdominal/extra-abdominal distant metastasis detection (last only by PET/CT). Eighteen (69.2 %) patients underwent PET/MRI for primary staging and eight patients (30.8 %) for re-staging their gynaecological malignancies. For primary tumour delineation, PET/MRI accuracy was statistically superior to PET/CT (p < 0.001). Among the different types of cancer, PET/MRI presented better tumour delineation mainly for cervical (6/7) and endometrial (2/3) cancers. PET/MRI for local evaluation as well as PET/CT for extra-abdominal metastases had therapeutic consequences in three and one patients, respectively. PET/CT detected 12 extra-abdominal distant metastases in 26 patients. PET/MRI is superior to PET/CT for primary tumour delineation. No differences were found in detection of regional lymph node involvement and abdominal metastases detection. • PET/MRI is superior to PET/CT for primary tumour delineation
 • PET/CT represents a reliable tool to detect extra-abdominal distant metastasis
 • PET/MRI might be the preferred imaging modality for staging cervical and endometrial tumours
 • Whole-body staging for detection and evaluation of extra-abdominal metastases is mandatory

PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison

In this paper the Eigenvalue Complementarity Problem (EiCP) with real symmetric matrices is addressed. It is shown that the symmetric (EiCP) is equivalent to finding an equilibrium solution of a differentiable optimization problem in a compact set. A necessary and sufficient condition for solvability is obtained which, when verified, gives a convenient starting point for any gradient-ascent local optimization method to converge to a solution of the (EiCP). It is further shown that similar results apply to the Symmetric Generalized Eigenvalue Complementarity Problem (GEiCP). Computational tests show that these reformulations improve the speed and robustness of the solution methods.

/pdf/the-symmetric-eigenvalue-complementarity-problem-2z6rcxy134.pdf

The symmetric eigenvalue complementarity problem

Positron emission tomography (PET)/MRI combines the functional ability of PET and the high soft tissue contrast of MRI. The aim of this study was to assess contrast-enhanced (ce)PET/MRI compared to cePET/CT in patients with suspected recurrence of head and neck cancer (HNC). Eighty-seven patients underwent sequential cePET/CT and cePET/MRI using a trimodality PET/CT-MRI set-up. Diagnostic accuracy for the detection of recurrent HNC was evaluated using cePET/CT and cePET/MRI. Furthermore, image quality, presence of unclear 18F-fluorodeoxy-D-glucose (FDG) findings of uncertain significance and the diagnostic advantages of use of gadolinium contrast enhancement were analysed. cePET/MRI showed no statistically significant difference in diagnostic accuracy compared to cePET/CT (91.5 vs 90.6 %). Artefacts’ grade was similar in both methods, but their location was different. cePET/CT artefacts were primarily located in the suprahyoid area, while on cePET/MRI, artefacts were more equally distributed among the supra and infrahyoid neck regions. cePET/MRI and cePET/CT showed 34 unclear FDG findings; of those 11 could be solved by cePET/MRI and 5 by cePET/CT. The use of gadolinium in PET/MRI did not yield higher diagnostic accuracy, but helped to better define tumour margins in 6.9 % of patients. Our data suggest that cePET/MRI may be superior compared to cePET/CT to specify unclear FDG uptake related to possible tumour recurrence in follow-up of patients after HNC. It seems to be the modality of choice for the evaluation of the oropharynx and the oral cavity because of a higher incidence of artefacts in cePET/CT in this area mainly due to dental implants. However, overall there is no statistically significant difference.

/pdf/pet-mri-and-pet-ct-in-follow-up-of-head-and-neck-cancer-fy1uudirll.pdf

Marcelo Queiroz

Papers

Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings

PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison

The symmetric eigenvalue complementarity problem

PET/MRI and PET/CT in follow-up of head and neck cancer patients

PET/MR in Cancers of the Head and Neck